Following through on its sweeping return to antibiotics R&D, Roche has agreed to pay up to $750 million to get its hands on an early-stage drug that helps existing treatments battle drug-resistant infections.
San Diego-based oncology diagnostics outfit Biocept is teaming up with Insight Genetics of Nashville to develop an improved diagnostic for the most common type of lung cancer.
Fast on the heels of the FDA's approval of Blincyto (blinatumomab), Amgen's new leukemia fighter that uses a bispecific T cell engager system to flag cancer cells for the immune system to destroy, the Big Biotech has partnered up with MD Anderson in Texas on a new program aimed at identifying targets for this technology in myelodysplastic syndrome.
Alnylam and Isis Pharmaceuticals announced an intellectual property cross-licensing agreement that they hope will leave them both better equipped to deal with the challenges of developing the first commercial RNAi therapy, including utilization of the promising but still-unproven RNA interference drug delivery pathway, and sometimes jittery investors.
23andMe's strategy of selling its database of genetic data to Big Pharma companies continues to bear fruit. The Google-backed company is sharing data about the DNA of 650,000 individuals with Pfizer to help that company in its R&D efforts.
Oncology biotech Mersana Therapeutics has expanded its relationship with Takeda, forging an agreement to develop targeted cancer drugs with as much as $300 million on the line.
Oracle announced that it will deploy Proteus' digital pill into its clinical trial data capture and management solution to track patient adherence to dosing instructions during trials, and provide insights into drug efficacy and safety. The development at the gargantuan JP Morgan Healthcare Conference in San Francisco is another win for ingestible devices, as well as Proteus, the recipient of a $172 million Series G financing in July last year.
Novartis, in the midst of a long-running effort to make clinical trials more efficient, has recruited Qualcomm to help it gather and store patient data from medical devices.
Novella Clinical, owned by Quintiles, struck a deal with the Cardiovascular Research Foundation to join forces on trial services, expanding their existing relationship to create a seamless offering for medical device developers.
At San Francisco's giant JP Morgan Healthcare Conference, tech company Qualcomm and Big Pharma player Novartis revealed a plan for a joint investment company with $100 million to spend on startups that "go beyond the pill."